Why Did Bill Ackman Buy Alphabet Stock?
Bill Ackman has become famous in the investing world for…
Sell
30
EDSA Quote, Financials, Valuation and Earnings
Last price:
$2.36
Seasonality move
:
-4.17%
Day range:
$2.33 - $2.39
52-week range:
$1.55 - $5.59
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
23.34x
P/B ratio:
12.92x
Volume:
4.2K
Avg. volume:
14K
1-year change:
-47.18%
Market cap:
$16.6M
Revenue:
--
EPS (TTM):
-$1.87
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target UpsideNo price target exists because of limited analyst coverage.
-
Price Target DownsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Edesa Biotech has 705.09% upside to fair value with a price target of $19.00 per share.
EDSA vs. S&P 500
-
Over the past 5 trading days, Edesa Biotech has underperformed the S&P 500 by -0.16% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Edesa Biotech does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Edesa Biotech revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Edesa Biotech reported revenues of --.
Earnings Growth
-
Edesa Biotech has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Edesa Biotech reported earnings per share of -$0.48.
Enterprise value:
16M
EV / Invested capital:
--
Price / LTM sales:
23.34x
EV / EBIT:
--
EV / Revenue:
48.64x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-3.20x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$15.6M | -$8M | -$6.2M | -$1.7M | -$1.6M | |
| EBITDA | -$15.5M | -$7.8M | -$6M | -$1.7M | -$1.6M | |
| Diluted EPS | -$6.88 | -$2.60 | -$1.87 | -$0.54 | -$0.48 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $7.7M | $9.9M | $9.1M | $5.4M | $2.1M | |
| Total Assets | $10.3M | $12.3M | $11.7M | $7.8M | $4.2M | |
| Current Liabilities | $906.3K | $1.7M | $1.3M | $2M | $1.9M | |
| Total Liabilities | $2.4M | $1.8M | $1.4M | $2M | $1.9M | |
| Total Equity | $7.9M | $10.5M | $10.3M | $5.8M | $2.3M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$10.9M | -$6.3M | -$5M | -$1.4M | -$1.5M | |
| Cash From Investing | -$2.5K | -- | -- | -- | -- | |
| Cash From Financing | $13.3M | $2.2M | $2.4M | $305.7K | $2.1M | |
| Free Cash Flow | -$10.9M | -$6.3M | -$5M | -$1.4M | -$1.5M | |
EDSA
Sector
Market Cap
$16.6M
$35M
Price % of 52-Week High
42.22%
44.47%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.9%
1-Year Price Total Return
-47.19%
-38.53%
Beta (5-Year)
0.603
0.738
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$2.32
200-day SMA
Sell
Level
$3.07
Bollinger Bands (100)
Buy
Level
1.83 - 2.43
Chaikin Money Flow
Sell
Level
-62.7M
20-day SMA
Buy
Level
$2.32
Relative Strength Index (RSI14)
Buy
Level
51.84
ADX Line
Buy
Level
18.01
Williams %R
Sell
Level
-12.1212
50-day SMA
Sell
Level
$2.37
MACD (12, 26)
Sell
Level
0.00
25-day Aroon Oscillator
Sell
Level
-44
On Balance Volume
Neutral
Level
159.4M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.
Stock Forecast FAQ
In the current month, EDSA has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The EDSA average analyst price target in the past 3 months is $19.00.
-
Where Will Edesa Biotech Stock Be In 1 Year?
According to analysts, the consensus estimate is that Edesa Biotech share price will rise to $19.00 per share over the next 12 months.
-
What Do Analysts Say About Edesa Biotech?
Analysts are divided on their view about Edesa Biotech share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Edesa Biotech is a Sell and believe this share price will drop from its current level to $17.00.
-
What Is Edesa Biotech's Price Target?
The price target for Edesa Biotech over the next 1-year time period is forecast to be $19.00 according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is EDSA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Edesa Biotech is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of EDSA?
You can purchase shares of Edesa Biotech via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Edesa Biotech shares.
-
What Is The Edesa Biotech Share Price Today?
Edesa Biotech was last trading at $2.36 per share. This represents the most recent stock quote for Edesa Biotech. Yesterday, Edesa Biotech closed at $2.36 per share.
-
How To Buy Edesa Biotech Stock Online?
In order to purchase Edesa Biotech stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Did Bill Ackman Buy Brookfield Stock?
Bill Ackman of Pershing Square Capital has made a number…
Why Is Chewy Stock Up — And Will It Keep Climbing?
We are all witnesses to the crazy e-commerce industry boom…
Stock Ideas
Buy
61
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 34x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
59
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 38x
Alerts
Sell
27
SAIA alert for Apr 26
Saia [SAIA] is down 30.77% over the past day.
Sell
48
APPF alert for Apr 26
AppFolio [APPF] is down 18.16% over the past day.
Sell
15
KNSL alert for Apr 26
Kinsale Capital Group [KNSL] is down 16.33% over the past day.
